Innovation Event


Kategorie: Life Sciences

Ort: Halle 7, Gundeldingerfeld, Dornacherstrasse 192, 4053 Basel

Stephan Emmerth

Ihre Kontaktperson

Stephan Emmerth

PhD | Senior Project Manager Biotech, Business Development Senior Manager BaseLaunch

Tel. +41 61 295 50 17

event Life Sciences


Eduard Holdener from Novimmune on challenges and opportunities by doing deals with big and midsize pharma

Novimmune is a privately held Swiss biotech founded in 1998 by the renowned immunologist Dr. Bernard Mach. More than 120 employees operate from two sites, Geneva and Basel, Switzerland, with the objective to provide innovative, antibody-based medicines to patients suffering from inflammatory diseases, immune-related disorders and cancer.

Landing licensing deals with big pharma industry is a lengthy and tedious process. Apparently, Novimmune knows how to master it: In 2010, Novimmune successfully signed an exclusive partnering deal with Genentech, followed by a second collaboration agreement six years later. In 2014, Tiziana Life Sciences licensed their anti-CD3 monoclonal antibody. In 2016 both companies signed a collaboration agreement. Novimmune also has a research collaboration with Baxalta Inc. (now Shire Inc.).

Dr. Eduard Holdener, CEO and Chairman of Novimmune and experienced pharma industry professional, talks about this story and shares insights on landing licensing deals in the pharma industry.

The event, organized by and the Life Science Network Basel, takes place at Halle 7, (Gundeldingerfeld, Dornacherstrasse 192) in Basel on October 19th, starting at 7:00 p.m. Doors are open at 6:45 p.m.


18:45 Door opening
19:00 Introduction
19:05 Talk by Eduard Holdener and Q&A
19:50 Networking apero

Registration is free of charge but compulsory via the registration button by October 16th.

About Eduard Hodener:

Dr. Holdener has served as Novimmune's Chairman since 2008. Prior to Novimmune, Eduard served as Global Head of Development and Chief Medical Officer of the Pharma Division at F. Hoffman-La Roche. He was instrumental in establishing and expanding Roche's therapeutic areas and in achieving several key international approvals for new medicines in oncology, virology, and rheumatology.

Before that, Eduard led Roche's development operations in Japan for three years and was a member of the Chugai Co. acquisition and integration team during the Roche/Chugai merger in 2001. He also established a new Roche clinical development center in Shanghai. Eduard holds a medical degree from the University of Zurich and completed a two-year fellowship in oncology at the University of Kansas Medical Center in Kansas City.

He joined Roche in 1986 after 14 years in academic medicine. Currently, Eduard also serves as a director of Parexel International and HBM Healthcare Investment, two publicly traded companies. He also served as a director of Syntaxin, Cellerix and Tigenix NV.

Cookies verwendet Cookies, um Ihnen den bestmöglichen Service zu gewähren. Wenn Sie auf der Seite weitersurfen, stimmen Sie der Cookie-Nutzung zu.